Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data

Grants

Funding Acknowledgements

We are deeply grateful to the probands, their families, clinical research coordinators, and referring physicians for their participation and provision of phenotype data, and DNA samples used in this study. We thank the EPGP Administrative (C Freyer, K Fox, R Fahlstrom, S Cristofaro, and K McGovern), Bioinformatics Core (G Nesbitt, K McKenna, and V Mays), staff at Coriell Institute - NINDS Genetics Repository, and members of the Institute for Genomic Medicine, Columbia University (P Cansler, J Charoensri, B Copeland, S Kamalakaran, J Keebler, B Krueger, C Malone, C Mebane, and M Cook) for their dedication and commitment to this work. We also thank R Stewart, K Gwinn, R Corriveau, B Fureman, and V Whittemore from the National Institute of Neurological Disorders and Stroke for their careful oversight and guidance of both EPGP and Epi4K. We thank the following organizations for assistance in publicizing EPGP; enabling us to recruit participants effectively: AED Pregnancy Registry, American Epilepsy Society, Association of Child Neurology Nurses, California School Nurses Organization, Child Neurology Society, Citizens United for Research in Epilepsy, Dravet Syndrome Foundation, Epilepsy Alliance of Orange County, Epilepsy Foundation, Epilepsy Therapy Project, Finding a Cure for Epilepsy and Seizures, IDEA League, InfantileSpasms.com, Lennox-Gastaut Syndrome Foundation, PatientsLikeMe, People Against Childhood Epilepsy, PVNH Support & Awareness, and Seizures& Epilepsy Education. We would like to acknowledge the following individuals or groups for the contributions of control samples: D Daskalakis; P Lugar; J Milner; T Young and K Whisenhunt; Z Farfel, D Lancet, and E Pras; W Lowe; R Gbadegesin and M Winn; K Schmader, S McDonald, HK White, and M Yanamadala; A Holden; E Behr; C Moylan; AM Diehl and M Abdelmalek; S Palmer; G Nestadt; J Samuels; Y Wang; M Carrington; M Harms; T Miller; A Pestronk; R Bedlack; R Brown; N Shneider; S Gibson; J Ravits; A Gilter; J Glass; F Baas; E Simpson; and G Rouleau; K Welsh-Bomer, C Hulette, J Burke; The ALS Sequencing Consortium; The Murdock Study Community Registry and Biorepository; M Connors, L Morris, and the CHAVI investigators; the Carol Woods and Crosdaile Retirement Communities; and DUHS (Duke University Health System) Nonalcoholic Fatty Liver Disease Research Database and Specimen Repository. The collection of control samples and data was funded in part by: Biogen Idec.; The Duke Chancellor's Discovery Program Research Fund 2014; Bill and Melinda Gates Foundation; The Division of Intramural Research; B57 SAIC-Fredrick Inc M11-074; Bryan ADRC NIA P30 AG028377; The Ellison Medical Foundation New Scholar award AG-NS-044108; National Institute of Mental Health (K01MH098126, R01MH097993); National Institute of Allergy and Infectious Diseases (1R56AI098588-01A1); and National Institute of Allergy and Infectious Diseases Center (U19AI067854, UM1-AI100645). We thank the NHLBI GO Exome Sequencing Project and its ongoing studies that produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926), and the Heart GO Sequencing Project (HL-103010).This work was supported by grants from the National Institute of Neurological Disorders and Stroke (The Epilepsy Phenome/Genome Project NS053998; Epi4K NS077364, NS077274, NS077303, and NS077276), The Andrew's Foundation, Finding a Cure for Epilepsy and Seizures, the Richard Thalheimer Philanthropic Fund, and the Eurocores program EuroEPINOMICS-RES of the European Science Foundation. The project received further support through grants from the Fund for Scientific Research Flanders (FWO); the Academy of Finland (141549); the Folkhalsan Research Foundation; the program 'Investissements d'avenir' ANR-10IAIHU-06; the Federal Ministry for Education and Research (IonNeurONet: 01GM1105), the German Research Foundation (DFG: HE5415/3-1; Le1030/111; RO3396/2-1), the German Society for Epileptology (DGfE), the Foundation noepilep.; the Swiss National Science Foundation (SNF: 32EP30_136042/1); the Wellcome Trust (09805); intramural funds of the University of Kiel; the Popgen 2.0 network (P2N) through the German Ministry for Education and Research (01EY1103); and the European Union through Seventh Framework Programme (FP7) under the project DESIRE (N602531). The project also received infrastructural support through the Institute of Clinical Molecular Biology in Kiel, supported in part by DFG Cluster of Excellence 'Inflammation at Interfaces' and 'Future Ocean'. Orrin Devinsky, David B Goldstein, Steve Petrou and Slave Petrovski have interests in companies related to epilepsy precision medicine.